WO2000002573A1 - Natural composition and method for the treatment of sexual dysfunction - Google Patents

Natural composition and method for the treatment of sexual dysfunction Download PDF

Info

Publication number
WO2000002573A1
WO2000002573A1 PCT/US1999/015534 US9915534W WO0002573A1 WO 2000002573 A1 WO2000002573 A1 WO 2000002573A1 US 9915534 W US9915534 W US 9915534W WO 0002573 A1 WO0002573 A1 WO 0002573A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
approximately
sexual dysfunction
ginseng
arginine
Prior art date
Application number
PCT/US1999/015534
Other languages
French (fr)
Other versions
WO2000002573A8 (en
Inventor
Melvin J. Duckett
Kyle Moore
Original Assignee
Duckett Melvin J
Kyle Moore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26785319&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2000002573(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Duckett Melvin J, Kyle Moore filed Critical Duckett Melvin J
Priority to AU14999/01A priority Critical patent/AU758888B2/en
Priority to EP99933828A priority patent/EP1143987A4/en
Priority to KR1020017000315A priority patent/KR20010074683A/en
Priority to JP2000558832A priority patent/JP2003527304A/en
Publication of WO2000002573A1 publication Critical patent/WO2000002573A1/en
Publication of WO2000002573A8 publication Critical patent/WO2000002573A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
    • A61K36/725—Ziziphus, e.g. jujube
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to the treatment of sexual dysfunction and, more particularly, to an improved natural composition and method for treatment of erectile dysfunction and female sexual dysfunction using a combination of L-arginine, ginseng and Zizyphi fructus in an orally administered dosage.
  • Erectile Dysfunction e.g., "the inability to achieve and/or maintain an erection sufficient for sexual activity” (New England Journal of Medicine). Erectile dysfunction is most often attributable to the inability to generate enough NO in the corpus cavernosum.
  • NO nitric oxide
  • the physiologic mechanism of erection of the penis involves release of nitric oxide (NO) in the corpus cavernosum during sexual stimulation. NO then activates the enzyme guanylate cyclase, which results in increased levels of cyclic guanosine monophosphate (cGMP), producing smooth muscle relaxation in the corpus cavernosum and allowing inflow of blood.
  • NO nitric oxide
  • cGMP cyclic guanosine monophosphate
  • Viagra ® is an oral drug for erectile dysfunction made by Pfizer, Inc. Viagra ® received FDA approval on March 27 1998, and has since Viagra ® has given new hope to over 30 million men that suffer from the problem. Viagra ® was proven effective in 7 out of 10 men in clinical trials.
  • Viagra ® is the citrate salt of sildenafil, a selective inhibitor of cyclic guanosinemonophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5).
  • Sildenafil citrate is designated chemically as l-[[3-(6,7-dihydro-l-methyl-7-oxo-3-propyl-lH-pyrazolo [4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methylpiperazine citrate and has the structural formula shown in FIG. 1.
  • Sildenafil citrate is a crystalline powder, and Viagra ® puts this in tablet form equivalent to 25 mg, 50 mg and 100 mg of sildenafil for oral administration.
  • each tablet contains the following inactive ingredients: microcrystalline cellulose, anhydrous dibasic calcium phosphate, croscarmellose sodium, magnesium stearate, hydroxypropyl methylcellulose, titanium dioxide, lactose, triacetin, and FD & C Blue #2 aluminum lake.
  • Sildenafil has no direct relaxant effect on isolated human corpus cavernosum, but enhances the effect of nitric oxide (NO) by inhibiting phosphodiesterase type 5 (PDE5), which is responsible for degradation of cGMP in the corpus cavernosum.
  • NO nitric oxide
  • PDE5 phosphodiesterase type 5
  • sildenafil causes increased levels of cGMP in the corpus cavernosum, resulting in smooth muscle relaxation and inflow of blood to the corpus cavernosum.
  • Viagra ® Although there are few known side-effects with Viagra ® , it is a drug that required full FDA approval, and physicians must prescribe its usage and dosage for their patients. Unfortunately, a significant stigma is attached to erectile dysfunction, and many of its sufferers simply will not seek medical help. Thus, Viagra ® remains unavailable to a large proportion of the affected population. It would be greatly advantageous to provide a natural and organic alternative treatment with the same or similar benefits, but without the same level of risk.
  • Viagra ® inhibits phosphodiesterase type 5 (PDE5), which slows the degradation of cGMP in the corpus cavernosum.
  • PDE5 phosphodiesterase type 5
  • the resulting increased levels of cGMP in the corpus cavernosum results in smooth muscle relaxation.
  • the NO is acted upon by the enzyme guanylate cyclase, which results in increased levels of cGMP, again producing smooth muscle relaxation in the corpus cavernosum and allowing inflow of blood.
  • guanylate cyclase Nitric Oxide as a Mediator of Relaxation of the Corpus Cavernosum in Response to
  • NO-nitro-L-arginine is an inhibitor of nitric oxide synthase, and studies have shown that concentrations of NO-nitro-L-arginine (3 x 10(-S) mol/1) can abolish relaxations. Moreover, the inhibitory effect of NO-nitro-L-arginine can be reversed in the presence of L-arginine (3 x 10(-3) mol/1). Simonsen et al., Nitric Oxide Is Involved in the Inhibitory Neurotransmission and Endothe Hum-dependent Relaxations of Human Small Penile Arteries, Clin. Sci. (Colch) 92:3, pp. 269-75 (March 1997). This research suggests that L-arginine can be an effective substrate for NO synthase, and may stimulate the release of NO in the corpus cavernosum.
  • L-arginine Beside the use of L-arginine, there is little to suggest how to stimulate the release of NO in the corpus cavernosum. It would be greatly advantageous to combine the use of L-arginine with other natural and organic constituents to stimulate enough release of NO in the corpus cavernosum to produce and sustain smooth muscle relaxation in the corpus cavernosum, allowing inflow of blood, and alleviating erectile dysfunction. It would also be advantageous to provide a composition as described above which is also effective for treating sexual conditions in females. It has been found that clitoral smooth muscle cells include many of the same morphological characteristics as the male corpus cavernosum, and should be physiologically responsive via the same messengers (cGMP) to promote smooth muscle relaxation. Park et al., Morphological/Biochemical Characterization of Human Corpus
  • an object of the present invention to provide a natural alternative to Viagra ® for the treatment of sexual dysfunction, and for generally increasing sexual performance in both males and females.
  • the above-described and other objects are accomplished by providing a combination of L-arginine, ginseng and zizyphi fructus in an orally administered dosage, these ingredients acting synergistically to stimulate enough release of NO in the corpus cavernosum and clitoris.
  • the combination when administered in proper concentration, works to allow the inflow of sufficient blood to promote smooth muscle relaxation.
  • the effect is sufficient in the corpus cavernosum to sustain smooth muscle relaxation and thereby eliminate erectile dysfunction in many persons. Based on research, it is believed that there will be beneficial results for female sexual dysfunction as well, and the composition will likely provide a remedy for many female conditions.
  • FIG. 1 illustrates the structural formula for Sildenafil citrate (Viagra ® ).
  • FIG. 2 is a flow diagram showing the comparative mechanisms by which Viagra ® and the present invention both stimulate increased levels of cGMP in the corpus cavernosum, resulting in smooth muscle relaxation and inflow of blood
  • RG1 enhances the production of NO for killing certain tumor cells See, e g , Fan et al , Enhancement of Nitric Oxide Production from Activated Macrophages by a Purified Form of Ginsenoside (Rgl), American Journal of Chinese Medicine, Vol XXHI, Nos 3-4 pp 279-287 (1995 Institute for Advanced Research in Asian Science and Medicine)
  • Zizyphi fructus a derivative of Zizyphi Seeds
  • increases NO production At least one study viewed the effects of Zizyphi fructus on NO generation on canines and found that Zizyphi fructus caused a concentration-dependent increase in NO The results suggest that Zizyphi fructus enhances airway (tracheal) ciliary motility and that this effect is exerted through the stimulation of epithelial NO generation See, Tamaoki et al , Zizyphi fructus, a Constituent of Antiasthmatic Herbal Medicine, Stimulates Airway Epithelial Ciliary Motility Through Nitric Oxide Generation, May-Jun, 22(3) 255-66, Exp Lung Res (1996)
  • the present inventors have found that the combination of Zizyphi fructus and ginseng (or its purified derivative ginsenoside or RG1) as described above, plus L-arginine, work synergistically to stimulate the release of NO in the corpus cavernosum to promote smooth muscle relaxation Each of the three constituents has an individual tendency to enhance the release of NO in the corpus cavernosum during sexual stimulation
  • the inventors have found that the synergy stems from a catalyst effect as illustrated in the flow diagram of FIG 2 the Zizyphi fructus and ginseng speed up the conversion of L-arginine to NO
  • the combination of Zizyphi fructus, ginseng (or its purified derivative ginsenoside or RG1) as described above, 5 plus L-arginine when administered in proper concentration, stimulate sufficient release of NO in the corpus cavernosum to allow the inflow of blood and alleviate erectile dysfunction.
  • L-arginine 200 mg (within a range of approximately 100-300 mg); ginseng: 100 mg (within a range of approximately 50-200 mg); Zizyphi fructus: 7.2 micrograms per mililiter (within a range of +/- 2.9 micrograms per mililiter). 1 25 Based on research, it is believed that the combination will have similar results in the female urological tract and will likely provide a remedy for many urological conditions.
  • the combined L-arginine, ginseng and Zizyphi fructus can be administered orally in liquid or tablet form, and thereby provides a safe, convenient and over-the- 30 counter remedy for sexual dysfunction.
  • the three constituents are purely organic, they have no known side-effects and have been time tested for other purposes.
  • Zizyphi fructus is derived primarily from the Tamaoki et al. Article, supra. product can be taken without a physician's prescription
  • sufferers of erectile dysfunction who choose not to seek medical help have a viable non-prescription alternative
  • additional organic ingredients are added to achieve incidental benefits
  • an amount of saw palmetto is added to help the nervous, respiratory and digestive systems
  • Saw palmetto is especially helpful for overcoming glandular weakness in general and to regenerate sexual glands in particular
  • Saw palmetto also contains a compound used by the body to manufacture cortisone
  • Cortisone is an adrenal hormone that helps regulate the metabolism of fats, carbohydrates (for energy), sodium and potassium (again for energy) and proteins, and it helps the body deal with inflammation
  • Gingko Biloba is an antioxidant and has been shown to increase blood flow to the brain, and thus improve memory and cognitive functions
  • Gingko Biloba increases blood flow to heart muscle, and protects that muscle from damage
  • Gingko Biloba relieves anxiety and depression, it can help vertigo and tinnitus (ringing in ears), and it may relieve asthma and allergy symptoms
  • Glutamic Acid is added as a protein supplement
  • the ingested protein is hydrolyzed by the digestive system and is then combined into the specific proteins needed for growth and to maintain good health
  • L- Alanine is added as well, as this amino acid aids in the metabolism of glucose (a simple carbohydrate that the body uses for energy)
  • L-Lysine may also be included as this protein supplement helps calcium absorption and maintains nitrogen balance
  • further inert ingredients may be added as desired to achieve a desired taste, color or consistency
  • Viagra ® is an popular oral drug for erectile dysfunction made by Pfizer, Inc Although there are few known side-effects with Viagra ® , it is a drug that required full United States Food and Drug Administration approval, and physicians must prescribe its usage and dosage for their patients Unfortunately, a significant stigma is attached to erectile dysfunction, and many of its sufferers simply will not seek medical help Thus, Viagra ® remains unavailable to a large proportion of the affected population There would be significant commercial advantage in providing a natural and organic alternative treatment with the same or similar benefits, but without the same level of risk It would also be advantageous to provide a composition as described above which is also effective for treating sexual conditions in females It has been found that clitoral smooth muscle cells include many of the same morphological characteristics as the male corpus cavernosum, and should be physiologically responsive via the same messengers (cGMP) to promote smooth muscle relaxation Thus, that which promotes smooth muscle relaxation in the corpus cavernosum, allowing inflow of blood, and alleviating erectile dysfunction, should work well to alleviate female sexual dysfunction

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A composition and method for treating sexual dysfunction by natural means using a combination of L-arginine, ginseng and Zizyphi fructus in an orally administered dosage. The combination works synergistically to alleviate erectile dysfunction by stimulating enough release of NO in the corpus cavernosum to produce and sustain smooth muscle relaxation, thereby allowing the inflow of blood and alleviating erectile dysfunction. Thus, a natural medicinal alternative to Viagra®* is provided for the treatment of erectile dysfuntion. The composition and method is also useful in treating sexual conditions in females.

Description

NATURAL COMPOSITION AND METHOD FOR THE TREATMENT OF
SEXUAL DYSFUNCTION
Technical Field
The present invention relates to the treatment of sexual dysfunction and, more particularly, to an improved natural composition and method for treatment of erectile dysfunction and female sexual dysfunction using a combination of L-arginine, ginseng and Zizyphi fructus in an orally administered dosage.
Background Art The most prevalent type of sexual dysfunction is "Erectile Dysfunction", e.g., "the inability to achieve and/or maintain an erection sufficient for sexual activity" (New England Journal of Medicine). Erectile dysfunction is most often attributable to the inability to generate enough NO in the corpus cavernosum. The physiologic mechanism of erection of the penis involves release of nitric oxide (NO) in the corpus cavernosum during sexual stimulation. NO then activates the enzyme guanylate cyclase, which results in increased levels of cyclic guanosine monophosphate (cGMP), producing smooth muscle relaxation in the corpus cavernosum and allowing inflow of blood.
There is one well-established solution. Viagra® is an oral drug for erectile dysfunction made by Pfizer, Inc. Viagra® received FDA approval on March 27 1998, and has since Viagra® has given new hope to over 30 million men that suffer from the problem. Viagra® was proven effective in 7 out of 10 men in clinical trials.
Viagra® is the citrate salt of sildenafil, a selective inhibitor of cyclic guanosinemonophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). Sildenafil citrate is designated chemically as l-[[3-(6,7-dihydro-l-methyl-7-oxo-3-propyl-lH-pyrazolo [4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methylpiperazine citrate and has the structural formula shown in FIG. 1. Sildenafil citrate is a crystalline powder, and Viagra® puts this in tablet form equivalent to 25 mg, 50 mg and 100 mg of sildenafil for oral administration. In addition to the active ingredient, sildenafil citrate, each tablet contains the following inactive ingredients: microcrystalline cellulose, anhydrous dibasic calcium phosphate, croscarmellose sodium, magnesium stearate, hydroxypropyl methylcellulose, titanium dioxide, lactose, triacetin, and FD & C Blue #2 aluminum lake.
Sildenafil has no direct relaxant effect on isolated human corpus cavernosum, but enhances the effect of nitric oxide (NO) by inhibiting phosphodiesterase type 5 (PDE5), which is responsible for degradation of cGMP in the corpus cavernosum. When sexual stimulation causes local release of NO, inhibition of PDE5 by sildenafil causes increased levels of cGMP in the corpus cavernosum, resulting in smooth muscle relaxation and inflow of blood to the corpus cavernosum.
Although there are few known side-effects with Viagra®, it is a drug that required full FDA approval, and physicians must prescribe its usage and dosage for their patients. Unfortunately, a significant stigma is attached to erectile dysfunction, and many of its sufferers simply will not seek medical help. Thus, Viagra® remains unavailable to a large proportion of the affected population. It would be greatly advantageous to provide a natural and organic alternative treatment with the same or similar benefits, but without the same level of risk.
It is known that the same or similar benefits can be achieved by a different mechanism than Viagra®. Again, Viagra® inhibits phosphodiesterase type 5 (PDE5), which slows the degradation of cGMP in the corpus cavernosum. The resulting increased levels of cGMP in the corpus cavernosum results in smooth muscle relaxation. In contrast, it is possible to foster smooth muscle relaxation directly by stimulating the release of NO in the corpus cavernosum during sexual stimulation. The NO in turn is acted upon by the enzyme guanylate cyclase, which results in increased levels of cGMP, again producing smooth muscle relaxation in the corpus cavernosum and allowing inflow of blood. See, e.g., Rajfer et al., Nitric Oxide as a Mediator of Relaxation of the Corpus Cavernosum in Response to
Nonadrenergic, Noncholinergic Neurotransmission, N. Engl. J. Med., 326(2), pp. 90-4 (Jan 9, 1992).
Notwithstanding there are relatively few studies that suggest how to stimulate the release of NO in the corpus cavernosum. It is recognized that NO-nitro-L-arginine is an inhibitor of nitric oxide synthase, and studies have shown that concentrations of NO-nitro-L-arginine (3 x 10(-S) mol/1) can abolish relaxations. Moreover, the inhibitory effect of NO-nitro-L-arginine can be reversed in the presence of L-arginine (3 x 10(-3) mol/1). Simonsen et al., Nitric Oxide Is Involved in the Inhibitory Neurotransmission and Endothe Hum-dependent Relaxations of Human Small Penile Arteries, Clin. Sci. (Colch) 92:3, pp. 269-75 (March 1997). This research suggests that L-arginine can be an effective substrate for NO synthase, and may stimulate the release of NO in the corpus cavernosum.
Beside the use of L-arginine, there is little to suggest how to stimulate the release of NO in the corpus cavernosum. It would be greatly advantageous to combine the use of L-arginine with other natural and organic constituents to stimulate enough release of NO in the corpus cavernosum to produce and sustain smooth muscle relaxation in the corpus cavernosum, allowing inflow of blood, and alleviating erectile dysfunction. It would also be advantageous to provide a composition as described above which is also effective for treating sexual conditions in females. It has been found that clitoral smooth muscle cells include many of the same morphological characteristics as the male corpus cavernosum, and should be physiologically responsive via the same messengers (cGMP) to promote smooth muscle relaxation. Park et al., Morphological/Biochemical Characterization of Human Corpus
Clitoral Smooth Muscle Cells in Culture, Journal, of Urology, v. 159, n. 5, sup. (June 1998). Thus, that which promotes smooth muscle relaxation in the corpus cavernosum, allowing inflow of blood, and alleviating erectile dysfunction, should work well to alleviate female sexual dysfunction. Indeed, women claim to experience benefit from Viagra® and clinical tests are now being performed.
Disclosure of Invention It is, therefore, an object of the present invention to provide a natural alternative to Viagra® for the treatment of sexual dysfunction, and for generally increasing sexual performance in both males and females.
It is another object to combine the use of L-arginine with other natural and organic constituents to stimulate increased release of NO in the corpus cavernosum to produce and sustain smooth muscle relaxation in the corpus cavernosum, allowing inflow of blood, and alleviating erectile dysfunction. According to the present invention, the above-described and other objects are accomplished by providing a combination of L-arginine, ginseng and zizyphi fructus in an orally administered dosage, these ingredients acting synergistically to stimulate enough release of NO in the corpus cavernosum and clitoris. The combination, when administered in proper concentration, works to allow the inflow of sufficient blood to promote smooth muscle relaxation. The effect is sufficient in the corpus cavernosum to sustain smooth muscle relaxation and thereby eliminate erectile dysfunction in many persons. Based on research, it is believed that there will be beneficial results for female sexual dysfunction as well, and the composition will likely provide a remedy for many female conditions.
Brief Description of Drawings Other objects, features, and advantages of the present invention will become more apparent from the following detailed description of the preferred embodiment and certain modifications thereof when taken together with the accompanying drawings in which:
FIG. 1 illustrates the structural formula for Sildenafil citrate (Viagra®). FIG. 2 is a flow diagram showing the comparative mechanisms by which Viagra® and the present invention both stimulate increased levels of cGMP in the corpus cavernosum, resulting in smooth muscle relaxation and inflow of blood
Best Mode(s) for Carrying Out the Invention Past studies with natural ingredients have shown that a few have a tendency to increase synthesis of NO levels While these studies have had various purposes, none have dealt with smooth muscle relaxation or sexual dysfunction
Examples of such studies with natural medicines include ginseng, ginsenoside, and its purified derivative RG1 It has been shown that RG1 enhances the production of NO for killing certain tumor cells See, e g , Fan et al , Enhancement of Nitric Oxide Production from Activated Macrophages by a Purified Form of Ginsenoside (Rgl), American Journal of Chinese Medicine, Vol XXHI, Nos 3-4 pp 279-287 (1995 Institute for Advanced Research in Asian Science and Medicine)
Another Chinese anti-asthmatic herbal medicine, Zizyphi fructus (jujube), a derivative of Zizyphi Seeds, increases NO production At least one study viewed the effects of Zizyphi fructus on NO generation on canines and found that Zizyphi fructus caused a concentration-dependent increase in NO The results suggest that Zizyphi fructus enhances airway (tracheal) ciliary motility and that this effect is exerted through the stimulation of epithelial NO generation See, Tamaoki et al , Zizyphi fructus, a Constituent of Antiasthmatic Herbal Medicine, Stimulates Airway Epithelial Ciliary Motility Through Nitric Oxide Generation, May-Jun, 22(3) 255-66, Exp Lung Res (1996)
The present inventors have found that the combination of Zizyphi fructus and ginseng (or its purified derivative ginsenoside or RG1) as described above, plus L-arginine, work synergistically to stimulate the release of NO in the corpus cavernosum to promote smooth muscle relaxation Each of the three constituents has an individual tendency to enhance the release of NO in the corpus cavernosum during sexual stimulation The inventors have found that the synergy stems from a catalyst effect as illustrated in the flow diagram of FIG 2 the Zizyphi fructus and ginseng speed up the conversion of L-arginine to NO Thus, the combination of Zizyphi fructus, ginseng (or its purified derivative ginsenoside or RG1) as described above, 5 plus L-arginine, when administered in proper concentration, stimulate sufficient release of NO in the corpus cavernosum to allow the inflow of blood and alleviate erectile dysfunction. While any of the three constituents taken alone would be insufficient to produce the desired result, in combination they work synergistically to produce significant NO. 10 As seen in the flow diagram of FIG. 2, the additional NO is converted by guanylate cyclase, resulting in increased levels of cyclic guanosine monophosphate (cGMP) in the corpus cavernosum. The cGMP in turn produces smooth muscle relaxation and improves arterial blood flow which results in an improved trapping of blood in the corpus cavernosum. The same mechanism should improve female sexual 15 conditions as well. See Park et al. , supra.
It should be understood that the proper relative concentrations of the three constituents may vary depending on the physical characteristics of each person. However, preliminary research suggests that the desired effect is best achieved with a single dose comprising the following preferred concentrations and known acceptable 20 ranges:
L-arginine: 200 mg (within a range of approximately 100-300 mg); ginseng: 100 mg (within a range of approximately 50-200 mg); Zizyphi fructus: 7.2 micrograms per mililiter (within a range of +/- 2.9 micrograms per mililiter).1 25 Based on research, it is believed that the combination will have similar results in the female urological tract and will likely provide a remedy for many urological conditions.
The combined L-arginine, ginseng and Zizyphi fructus can be administered orally in liquid or tablet form, and thereby provides a safe, convenient and over-the- 30 counter remedy for sexual dysfunction. The three constituents are purely organic, they have no known side-effects and have been time tested for other purposes. The
1 The preferred concentration of Zizyphi fructus is derived primarily from the Tamaoki et al. Article, supra. product can be taken without a physician's prescription Thus, sufferers of erectile dysfunction who choose not to seek medical help have a viable non-prescription alternative
In the preferred embodiment, additional organic ingredients are added to achieve incidental benefits For instance, an amount of saw palmetto is added to help the nervous, respiratory and digestive systems Saw palmetto is especially helpful for overcoming glandular weakness in general and to regenerate sexual glands in particular It is a well-known dietary aid for increasing male prostate health Saw palmetto also contains a compound used by the body to manufacture cortisone Cortisone is an adrenal hormone that helps regulate the metabolism of fats, carbohydrates (for energy), sodium and potassium (again for energy) and proteins, and it helps the body deal with inflammation
Furthermore, an amount of Gingko Biloba is added Gingko Biloba is an antioxidant and has been shown to increase blood flow to the brain, and thus improve memory and cognitive functions Gingko Biloba increases blood flow to heart muscle, and protects that muscle from damage Gingko Biloba relieves anxiety and depression, it can help vertigo and tinnitus (ringing in ears), and it may relieve asthma and allergy symptoms
Glutamic Acid is added as a protein supplement The ingested protein is hydrolyzed by the digestive system and is then combined into the specific proteins needed for growth and to maintain good health
An amount of L- Alanine is added as well, as this amino acid aids in the metabolism of glucose (a simple carbohydrate that the body uses for energy)
An amount of L-Lysine may also be included as this protein supplement helps calcium absorption and maintains nitrogen balance Of course, in addition to the above-described active ingredients, further inert ingredients may be added as desired to achieve a desired taste, color or consistency
Having now fully set forth the preferred embodiment and certain modifications of the concept underlying the present invention, various other embodiments as well as certain variations and modifications of the embodiments herein shown and described will obviously occur to those skilled in the art upon becoming familiar with said underlying concept It is to be understood, therefore, that the invention may be practiced otherwise than as specifically set forth in the appended claims
Industrial Applicability
Viagra® is an popular oral drug for erectile dysfunction made by Pfizer, Inc Although there are few known side-effects with Viagra®, it is a drug that required full United States Food and Drug Administration approval, and physicians must prescribe its usage and dosage for their patients Unfortunately, a significant stigma is attached to erectile dysfunction, and many of its sufferers simply will not seek medical help Thus, Viagra® remains unavailable to a large proportion of the affected population There would be significant commercial advantage in providing a natural and organic alternative treatment with the same or similar benefits, but without the same level of risk It would also be advantageous to provide a composition as described above which is also effective for treating sexual conditions in females It has been found that clitoral smooth muscle cells include many of the same morphological characteristics as the male corpus cavernosum, and should be physiologically responsive via the same messengers (cGMP) to promote smooth muscle relaxation Thus, that which promotes smooth muscle relaxation in the corpus cavernosum, allowing inflow of blood, and alleviating erectile dysfunction, should work well to alleviate female sexual dysfunction as well

Claims

Claims
A composition for alleviating sexual dysfunction, comprising L-arginine, ginseng and Zizyphi fructus, said constituents being administered to stimulate release of NO in the human body to produce smooth muscle relaxation
The composition for alleviating sexual dysfunction according to claim 1 , wherein said constituents are administered orally in a single dose including a range of approximately 100-300 mg of said L-arginine, a range of approximately 50-200 mg of said ginseng, and a range of approximately 4 3- 10 1 micrograms per milliliter of Zizyphi fructus
The composition for alleviating sexual dysfunction according to claim 2, wherein said composition includes approximately 200 mg of said L-arginine, approximately 100 mg of said ginseng, and approximately 7 2 micrograms per milliliter of Zizyphi fructus
The composition for alleviating sexual dysfunction according to claim 2, wherein said dose is in pill form for oral administration
The composition for alleviating sexual dysfunction according to claim 2, wherein said dose is in liquid form for oral administration
The composition for alleviating sexual dysfunction according to claim 1, further comprising Saw Palmetto
The composition for alleviating sexual dysfunction according to claim 1, further comprising Ginkgo Biloba
The composition for alleviating sexual dysfunction according to claim 1, further comprising L-Alanine.
9. The composition for alleviating sexual dysfunction according to claim 1, further comprising Glutamic Acid.
10. The composition for alleviating sexual dysfunction according to claim 1, further comprising L-Lysine.
11. A method for treating erectile dysfunction, comprising the steps of: combining L-arginine, ginseng, and Zizyphi fructus in a mixture; orally administering said mixture to stimulate release of NO in the human body and to thereby produce smooth muscle relaxation.
12. The method for treating erectile dysfunction according to claim 11, wherein said mixture of Zizyphi fructus, ginseng and L-arginine, work synergistically to stimulate the release of NO in the corpus cavernosum to promote smooth muscle relaxation.
13. The method for treating erectile dysfunction according to claim 12, wherein said mixture operates by a catalyst effect to stimulate sufficient release of NO in the corpus cavernosum to allow the inflow of blood and alleviate erectile dysfunction.
14. The method for treating erectile dysfunction according to claim 11, wherein said mixture is administered in a single dose including a range of approximately 100-300 mg of said L-arganine, a range of approximately 50-
200 mg of said ginseng, and a range of approximately 4.3-10.1 micrograms per mililiter of Zizyphi fructus.
15. The method for treating erectile dysfunction according to claim 14, wherein said dose further comprises approximately 200 mg of said L-arginine, approximately 100 mg of ginseng, and approximately 7.2 micrograms per milliliter of Zizyphi fructus.
PCT/US1999/015534 1998-07-09 1999-07-09 Natural composition and method for the treatment of sexual dysfunction WO2000002573A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU14999/01A AU758888B2 (en) 1998-07-09 1999-07-09 Natural composition and method for the treatment of sexual dysfunction
EP99933828A EP1143987A4 (en) 1998-07-09 1999-07-09 Natural composition and method for the treatment of sexual dysfunction
KR1020017000315A KR20010074683A (en) 1998-07-09 1999-07-09 Natural composition and method for the treatment of sexual dysfunction
JP2000558832A JP2003527304A (en) 1998-07-09 1999-07-09 Natural compositions and methods for treating sexual dysfunction

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9214398P 1998-07-09 1998-07-09
US60/092,143 1998-07-09
US09/255,587 US6007824A (en) 1998-07-09 1999-02-22 Natural composition and method for the treatment of sexual dysfunction
US09/255,587 1999-02-22

Publications (2)

Publication Number Publication Date
WO2000002573A1 true WO2000002573A1 (en) 2000-01-20
WO2000002573A8 WO2000002573A8 (en) 2001-02-15

Family

ID=26785319

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/015534 WO2000002573A1 (en) 1998-07-09 1999-07-09 Natural composition and method for the treatment of sexual dysfunction

Country Status (6)

Country Link
US (2) US6007824A (en)
EP (1) EP1143987A4 (en)
JP (1) JP2003527304A (en)
KR (1) KR20010074683A (en)
AU (1) AU758888B2 (en)
WO (1) WO2000002573A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100406287B1 (en) * 2001-06-14 2003-11-17 이형훈 Prostate washing-liquid composition
WO2003094944A1 (en) * 2002-05-10 2003-11-20 Indena S.P.A. Formulations useful in the treatment of male and female impotence
JP2005529915A (en) * 2002-05-10 2005-10-06 インデナ・ソチエタ・ペル・アチオニ Formulations useful in the treatment of male and female impotence
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
US8835413B2 (en) 2004-10-20 2014-09-16 Endorecherche, Inc. Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cGMP phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women
US9486482B2 (en) 2009-05-06 2016-11-08 Enovate Biolife Private Limited Herbal composition for treating male sexual dysfunction

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958926A (en) 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US6331543B1 (en) * 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
USRE37234E1 (en) 1996-11-01 2001-06-19 Nitromed, Inc. Nitrosated and nitrosylated phosphodiestrase inhibitor compounds, compositions and their uses
US7101857B2 (en) * 1996-11-05 2006-09-05 Gp Medical, Inc. Crosslinkable biological material and medical uses
US6998418B1 (en) 1996-11-05 2006-02-14 Gp Medical, Inc. Acellular biological material chemically treated with genipin
US6472425B1 (en) 1997-10-31 2002-10-29 Nitromed, Inc. Methods for treating female sexual dysfunctions
WO1999051252A1 (en) * 1998-04-03 1999-10-14 The Daily Wellness Company Compositions comprising l-arginine, ginseng and gingko biloba for enhancing blood circulation
US20050196470A9 (en) * 1998-04-03 2005-09-08 Wuh Hank C Method and composition for enhancing sexual desire
US7371415B1 (en) * 1998-04-03 2008-05-13 The Daily Wellness Company Method and composition for improving sexual fitness
FR2786699B1 (en) * 1998-12-02 2002-10-04 Philippe Gorny MEDICINE, IN PARTICULAR FOR PREVENTING OR TREATING SEXUAL DYSFUNCTIONS
WO2000053148A2 (en) * 1999-03-08 2000-09-14 Merck & Co., Inc. Methods and compositions for treating erectile dysfunction
EP1173167A4 (en) 1999-04-30 2004-07-14 Lilly Icos Llc Treatment of female arousal disorder
US20010003120A1 (en) * 1999-05-14 2001-06-07 M. D. Robert Hines Method for treating erectile dysfunction
US6702733B1 (en) 1999-07-01 2004-03-09 40 J's Llc Expanded clitoral sensitizing compounds with methods and apparatus for the delivery of these compounds
US6548087B1 (en) * 1999-07-12 2003-04-15 Frances B. Kent Nutritional supplement
US6627227B2 (en) * 2000-05-09 2003-09-30 Kenneth Weisman Use of saw palmetto to prevent atherosclerosis
US20040137081A1 (en) * 2003-01-13 2004-07-15 Peter Rohdewald Attaining sexual wellness and health of the sexual vascular system with proanthocyanidins
US6565851B2 (en) * 2000-05-26 2003-05-20 Horphag Research Limited Relieving symptoms of erectile dysfunction with proanthocyanidins
FR2809623B1 (en) * 2000-06-05 2003-09-05 Sanjuan Benito Arranz IN THE TREATMENT OF NEURODEGENERATIVE DISEASES: (ESPECIALLY ALZHEIMER AND PARKINSON), USE FOR A MEDICINAL PRODUCT: SILDENAFIL (OR DERIVATIVES THEREOF)
US6737084B2 (en) 2000-06-27 2004-05-18 Qualilife Compositions and methods for enhancing or treating female sexual response
US7128930B1 (en) * 2000-09-01 2006-10-31 Meir S. Sacks Compositions and methods for treating sexual dysfunction
US6497885B2 (en) * 2000-12-22 2002-12-24 The Daily Wellness Company Method and composition for improving fertility health in female and male animals and humans
US6989164B2 (en) 2000-12-22 2006-01-24 The Daily Wellness Company Method and composition for improving male fertility health
US6338862B1 (en) * 2001-03-26 2002-01-15 Sarfaraz K Niazi Composition and method of use in treating sexual dysfunction using cGMP-specific phosphodiesterase type 5 inhibitors
DE10124631C1 (en) * 2001-05-18 2002-11-21 Atotech Deutschland Gmbh Direct electrolytic metallization of insulating substrate surface, used in circuit board production, e.g. for metallizing fine holes, uses pretreatment with water-soluble polymer and acid solutions of permanganate and thiophen compound
US6444237B1 (en) 2001-09-13 2002-09-03 Pamela A. Heleen Herbal composition for enhancing sexual response
US6548545B1 (en) 2001-10-01 2003-04-15 40 J's Llc Treatment of interstitial cystitis using topical application of menthol and L-arginine
US6472390B1 (en) * 2001-11-13 2002-10-29 Duke University Use of therapeutic dosages for nitric oxide donors which do not significantly lower blood pressure or pulmonary artery pressure
US20040110691A1 (en) * 2001-11-13 2004-06-10 Stamler Jonathan S. Thiol reactive agents as a therapeutic modality
US6627602B2 (en) * 2001-11-13 2003-09-30 Duke University Preventing desensitization of receptors
US6706756B1 (en) 2001-11-16 2004-03-16 University Of South Florida Vasodilating compound and method of use
US7258877B2 (en) * 2001-12-21 2007-08-21 Sunten Phytotech Co., Ltd. Herbal pharmaceutical composition for treatment of cardiovascular disease
TWI275397B (en) * 2001-12-21 2007-03-11 Sun Ten Pharmaceutical Co Ltd Herbal composition, use thereof in protection of endothelial cell and in anti-inflammation, and preparation method thereof
KR100488511B1 (en) * 2002-05-09 2005-05-11 에스티케이제약 주식회사 Health supplement including nature medicine ingredients and the composition thereof.
US7214390B2 (en) * 2003-02-07 2007-05-08 Barmensen Labs, Llc Topical compositions for enhancing sexual responsiveness
MXPA05010068A (en) * 2003-03-21 2005-11-23 Nexmed Holdings Inc Angiogenesis promotion by prostaglandin compositions and methods.
AU2004224413A1 (en) * 2003-03-21 2004-10-07 Nexmed (Holdings), Inc. Prostaglandin compositions for the treatment of erectile dysfunction
KR20050048940A (en) * 2003-11-20 2005-05-25 곽용근 Composition comprising a magnesium compound and/or a magnesium salt for improving sexual dysfunction
WO2006026325A2 (en) * 2004-08-26 2006-03-09 Pathak Chandrashekhar P Implantable tissue compositions and method
CN101175529A (en) * 2005-05-19 2008-05-07 埃-皮尔制药公司 Ingestible device for nitric oxide production in tissue
EA200802440A1 (en) 2006-06-06 2009-06-30 Олег Ильич ЭПШТЕЙН Drug for the treatment of obesity, diabetes mellitus and diseases with impaired glucose tolerance
CA2609626A1 (en) * 2006-12-06 2008-02-05 H3 Formulations Ltd. Composition comprising l-arginine, crataegus, artichoke flavonoids and citruilline for improving blood flow in working muscles
WO2008126088A2 (en) * 2007-04-15 2008-10-23 Oron Zachar Anti-pyretic vasodilators
KR101030608B1 (en) * 2007-05-11 2011-04-20 (주)아모레퍼시픽 Composition containing ginseng berry extract for improving sexual function
US9314493B2 (en) 2007-05-28 2016-04-19 Amorepacific Corporation Method for treating vascular inflammation, improving skin beauty and improving male sexual function using ginseng berry
KR20080104600A (en) * 2007-05-28 2008-12-03 (주)아모레퍼시픽 Composition for treatment of ischemic heart disease, facilitation of blood circulation and angiogenesis
KR100915786B1 (en) * 2007-07-21 2009-09-11 전현철 The Saw Palmetto Tea bag Contain oyster and bean
KR101614110B1 (en) 2008-11-28 2016-04-21 (주)아모레퍼시픽 Composition For Preventing or Treating Arteriosclerosis
JP2010163426A (en) * 2008-12-18 2010-07-29 Daiichi Sankyo Healthcare Co Ltd Medicinal composition containing phosphodiesterase-5 inhibitor and arginine
WO2011041542A2 (en) 2009-09-30 2011-04-07 Ultimaxx, Inc. Herbal pain killer compositions
KR100942794B1 (en) * 2009-11-03 2010-02-18 한남대학교 산학협력단 Arginine derivative and its salt showing the effect of improving sexual functions, composition for improving sexual functions comprising the same, and the manufacturing method thereof
US8821948B2 (en) * 2010-03-04 2014-09-02 Steva A. Komeh-Nkrumah Therapeutic, bio-affecting and body treating composition
US20120093950A1 (en) 2010-10-19 2012-04-19 Klrm, Llc Compositions and methods for treating, inhibiting the onset, and slowing the progression of erectile dysfunction including naturally occuring age related erectile dysfunction
US8940794B2 (en) 2011-04-07 2015-01-27 Nexmed Holdings, Inc. Methods and compositions for treating Raynaud's disease
WO2014163402A1 (en) * 2013-04-02 2014-10-09 주식회사 아모레퍼시픽 Composition for improving health and quality of life of women containing ginseng berry extract
US10226418B2 (en) 2014-05-12 2019-03-12 Susie Q, Ltd. Arginine-containing topical composition
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
JP7229767B2 (en) * 2018-12-28 2023-02-28 小林製薬株式会社 oral composition
US20240000808A1 (en) * 2020-11-16 2024-01-04 Orcosa Inc. Improved use of cannabinoids in the treatment of alzheimer's disease
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5439938A (en) * 1993-04-07 1995-08-08 The Johns Hopkins University Treatments for male sexual dysfunction
US5861168A (en) * 1993-06-11 1999-01-19 The Board Of Trustees Of The Leland Stanford Junior University Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEVALLIER A: "THE ENCYCLOPEDIA OF MEDICINAL PLANTS", ENCYCLOPEDIA OF MEDICINAL PLANTS, XX, XX, 1 January 1996 (1996-01-01), XX, pages 114 - 116 + 281 + 316, XP002924904 *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100406287B1 (en) * 2001-06-14 2003-11-17 이형훈 Prostate washing-liquid composition
JP4733385B2 (en) * 2002-05-10 2011-07-27 インデナ・ソチエタ・ペル・アチオニ Combinations useful for the treatment of impotence in men and women
JP2005530769A (en) * 2002-05-10 2005-10-13 インデナ・ソチエタ・ペル・アチオニ Combinations useful for the treatment of incompetence in men and women
US7361370B2 (en) 2002-05-10 2008-04-22 Indena S.P.A. Formulations useful in the treatment of male and female impotence
US7438934B2 (en) 2002-05-10 2008-10-21 Indena S.P.A. Formulations useful in the treatment of male and female impotence
WO2003094944A1 (en) * 2002-05-10 2003-11-20 Indena S.P.A. Formulations useful in the treatment of male and female impotence
JP2005529915A (en) * 2002-05-10 2005-10-06 インデナ・ソチエタ・ペル・アチオニ Formulations useful in the treatment of male and female impotence
US10076525B2 (en) 2004-10-20 2018-09-18 Endorecherche, Inc. Sex steroid precursors alone or in combination with selective estrogen receptor modulators for the prevention and treatment of dyspareunia in postmenopausal women
US10478443B2 (en) 2004-10-20 2019-11-19 Endorecherche, Inc. Sex steroid precursors alone or in combination with selective estrogen receptor modulators for the prevention and treatment of sexual dysfunction in postmenopausal women
US8835413B2 (en) 2004-10-20 2014-09-16 Endorecherche, Inc. Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cGMP phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women
US8629129B2 (en) 2007-08-10 2014-01-14 Endorecherche, Inc. Pharmaceutical compositions
US8957054B2 (en) 2007-08-10 2015-02-17 Endorecherche, Inc. Pharmaceutical compositions
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
US10881650B2 (en) 2007-08-10 2021-01-05 Endorecherche, Inc. Pharmaceutical compositions
US9486482B2 (en) 2009-05-06 2016-11-08 Enovate Biolife Private Limited Herbal composition for treating male sexual dysfunction

Also Published As

Publication number Publication date
JP2003527304A (en) 2003-09-16
US6007824A (en) 1999-12-28
AU1499901A (en) 2001-04-10
EP1143987A1 (en) 2001-10-17
EP1143987A4 (en) 2004-09-22
KR20010074683A (en) 2001-08-09
US6340480B1 (en) 2002-01-22
WO2000002573A8 (en) 2001-02-15
AU758888B2 (en) 2003-04-03

Similar Documents

Publication Publication Date Title
AU758888B2 (en) Natural composition and method for the treatment of sexual dysfunction
US7115285B2 (en) Composition and method for appetite and craving suppression and mood enhancement
WO2006002096A2 (en) Low doses of l-citrulline for treating diseases
US20230022324A1 (en) Compositions and methods to regulate hormonal cascades in stress disorders
US6338862B1 (en) Composition and method of use in treating sexual dysfunction using cGMP-specific phosphodiesterase type 5 inhibitors
EP1652520B1 (en) Formulations useful in the treatment of male and female impotence
JP2004536822A (en) Methods and compositions for enhancing libido
JPH0344324A (en) Sexual function invigorator
JPH09157163A (en) Amino acid composition and its ingestion
WO2016124080A1 (en) Use of 20(r)-ginsenoside rg3 in preparation of drug for preventing or/and treating obesity and drug
KR20160048812A (en) A dietary supplement comprising amino acids in a palatable liquid formulation that promotes restful sleep, recovery from stress and exercise and strengthens the immune system
TWI693939B (en) Composition for invigorating kidney and strengthening yang, preparation method and application thereof
JPH10114665A (en) Improver for aqueous body fluid and composition for oral administration comprising the same
CN100408038C (en) Use of a vitamin combination for the treatment of primary headaches
CN109223766A (en) Improve the composition and preparation process that microcirculation in human body improves the immunity of the human body
CN114010699B (en) Traditional Chinese medicine composition for treating hypertension and preparation method thereof
US20230025468A1 (en) Method and a dietary composition on regulation, treatment, and prevention of obesity
JPH0235057A (en) Functional food
JPH10114652A (en) Improver for aqueous body fluid and composition for oral administration comprising the same
JPWO2021062264A5 (en)
CN114177163A (en) Medicine for treating hypertension
RU1816217C (en) Biostimulant
CN104208115A (en) Traditional Chinese medicine composition prepared from dried sandalwood and ixeris sonchifolia
CN116549520A (en) Qi-blood tonifying, lung heat clearing and cough relieving traditional Chinese medicine formula, traditional Chinese medicine liquid and traditional Chinese medicine preparation
CN109349608A (en) A kind of health care preparation having both conditioning prospermia of males and the effect of fat reducing sports

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 558832

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1020017000315

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 14999/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999933828

Country of ref document: EP

AK Designated states

Kind code of ref document: C1

Designated state(s): AU BR CA CN ID IN JP KR MX NZ SG ZA

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 03/2000 UNDER (81) ADD "AU, BR, CN, ID, IN, KR, MX, NZ, SG, ZA" AND UNDER (84) ADD "EA (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)"; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 1020017000315

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1999933828

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 14999/01

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1999933828

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1020017000315

Country of ref document: KR